Lantern Pharma CEO Panna Sharma to Showcase AI Platform at Drug Repositioning, Repurposing and Rescue Conference

September 18, 2019 08:00 ET

Presentation to highlight use of machine learning, genomics and AI in building Lantern’s oncology drug portfolio and in developing insights about biological mechanisms, biomarker signatures and patient stratification strategies.

DALLAS and KEARNY, N.J., Sept. 18, 2019 (GLOBE NEWSWIRE) — Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, announced that its Chief Executive Officer, Panna Sharma, will present at the 8th Annual Drug Repositioning, Repurposing and Rescue Conference in Arlington, VA.

Mr. Sharma will present a talk entitled “How Machine Learning, Genomics and AI are Revolutionizing Cancer Drug Development” on Tuesday, September 24, 2019 at 2:45pm ET. Specifically, Sharma will elaborate on why now is an opportune moment for the pharmaceutical industry to leverage these technologies, and how Lantern Pharma is revolutionizing the drug development process by implementing its AI-enabled platform, RADR™, to increase clinical trial success rates and reduce timelines and costs. He will also share specifics from how Lantern has leveraged RADR™, Lantern’s AI platform, to rescue and accelerate efforts on Lantern’s clinical and preclinical stage programs.

Lantern currently has three drugs in its portfolio (LP100, LP184, LP300) and is using RADR™ to identify specific patient populations and potential combination mechanisms that are most likely to indicate the highest likelihood of response to that drug, as well as accelerate and de-risk the drug development and rescue process. This targeted approach, according to the company, will help drive down the cost of drug development and improve patient outcomes in cancer drug development and clinical trials. RADR™ is also used to aid in the rapid development of companion diagnostics (CDx), reducing the time and cost of bringing these cancer drugs to market, which would also positively impact the pharmaceutical, payer and patient community.

“The Drug Repositioning, Repurposing and Rescue Conference provides an excellent setting for the exchange of ideas and progress between pioneers in drug repurposing,” said Panna Sharma, CEO of Lantern Pharma. “Lantern is working diligently to repurpose cancer drugs, and we’ve made significant progress in the last year with respect to early-stage clinical results and the constant evolution of our platform. We look forward to presenting this progress at this year’s conference.”

The annual Drug Repositioning, Repurposing and Rescue Conference gathers some of the foremost experts in the fields of repositioning and repurposing to discuss patient advocacy efforts, partnerships, systematic repositioning and data analytics, new technologies, regulation and key areas for repurposing.

For more information, visit

About Lantern Pharma

Lantern Pharma is a clinical stage biotech innovating the repurposing, revitalization and development of precision therapeutics in oncology. Lantern leverages advances in machine learning, genomics and artificial intelligence by using a proprietary AI platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern’s focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Lantern seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver cancer therapies to patients as quickly and efficiently as possible.

Lantern’s current therapy product pipeline consists of three drugs, two in clinical stages and one in preclinical, all focusing on cancers that have unique and unmet clinical needs with a clearly defined patient population. Lantern believes that the use of machine learning, genomics and computational methods can help accelerate the development and commercialization of small molecule-based therapies. These drugs can be targeted to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, thereby achieving better outcomes. For more information, please visit the company’s website at or view company updates on Twitter and LinkedIn.


Kyle Evans

FischTank Marketing and PR


p: 646-699-1414

Let’s start a conversation about the future of cancer drug development.

We are a biotech pharma at the intersection of Artificial Intelligence, genomics, and oncology drug development.

Contact Us